Adjuvant targeted therapy in high-risk stage IB epidermal growth factor receptor-mutant lung cancer: Role of ground-glass opacity components.

In the ADAURA trial, patients with stage IB demonstrated a favorable trend in 5-year OS (94% vs 88%, hazard ratio [HR], 0.44; 95% CI, 0.17-1.02). 6 However, the magnitude and consistency of the benefit of adjuvant targeted therapy (ATT) in this subgroup remain ambiguous when compared with adjuvant chemotherapy (ACT) or placebo, particularly in terms of OS. 9 Emerging data

also in 993 other papers